{"id":744027,"date":"2020-01-31T16:05:00","date_gmt":"2020-01-31T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/"},"modified":"2025-03-07T23:37:40","modified_gmt":"2025-03-08T04:37:40","slug":"dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/","title":{"rendered":"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Christine (\u201cKricket\u201d) E. Seidman, professor, Harvard Medical School, and Kathy J. Warden, chairman, chief executive officer and president, Northrop Grumman Corporation, will join the company\u2019s Board of Directors effective March 16, 2020. Dr. Seidman and Ms. Warden will stand for election with the company\u2019s other directors in connection with Merck\u2019s Annual Meeting of Shareholders on May 26, 2020. With the addition of Dr. Seidman and Ms. Warden, the Merck board will include 14 members.\n<\/p>\n<p>\n\u201cWe are pleased to welcome Dr. Seidman and Ms. Warden to our board,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cBoth are highly respected leaders in their fields. Dr. Seidman\u2019s scientific expertise and Ms. Warden\u2019s strategic perspective and operational expertise will be important assets as Merck continues its journey to become the premier research-intensive biopharmaceutical company serving patients around the globe.\u201d\n<\/p>\n<p>\nDr. Seidman is the Thomas W. Smith Professor of Medicine and Genetics at Harvard Medical School and is the director of the Cardiovascular Genetics Program at Brigham and Women\u2019s Hospital. She leads a research laboratory that focuses on integrating clinical medicine and molecular technologies to define disease-causing gene mutations and genetic variations that increase disease risk. Dr. Seidman was awarded the Vanderbilt Prize in Biomedical Sciences in 2018 and elected to the National Academy of Sciences in 2005. She earned her degree in biochemistry from Harvard University, her M.D. from The George Washington University and completed her residency in internal medicine at Johns Hopkins University.\n<\/p>\n<p>\nMs. Warden became chairman of Northrop Grumman in August 2019 and has served as CEO and President since January 2019. Previously, she was President and Chief Operating Officer, and President of the Mission Systems and Information Systems sectors. Prior to joining Northrop Grumman, Ms. Warden held leadership roles at General Dynamics, a venture technology firm, and General Electric.\n<\/p>\n<p>\nIn addition to global operational experience leading a research and technology-intensive company, Ms. Warden brings deep cybersecurity expertise to the Merck board. Ms. Warden also serves as the chair of the Board of Directors of the Federal Reserve Bank of Richmond. She earned her undergraduate degree in computer information systems from James Madison University and her MBA from The George Washington University.\n<\/p>\n<p>\n<b>About Merck<\/b>\n<\/p>\n<p>\nFor more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world &#8211; including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>, <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>, <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>, <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2018 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p> Media: <br \/>Jennifer Mauer <br \/>(908) 740-1801 <\/p>\n<p>Investors: <br \/>Peter Dannenbaum <br \/>(908) 740-1037 <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Christine (\u201cKricket\u201d) E. Seidman, professor, Harvard Medical School, and Kathy J. Warden, chairman, chief executive officer and president, Northrop Grumman Corporation, will join the company\u2019s Board of Directors effective March 16, 2020. Dr. Seidman and Ms. Warden will stand for election with the company\u2019s other directors in connection with Merck\u2019s Annual Meeting of Shareholders on May 26, 2020. With the addition of Dr. Seidman and Ms. Warden, the Merck board will include 14 members. \u201cWe are pleased to welcome Dr. Seidman and Ms. Warden to our board,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cBoth are highly respected leaders in their fields. Dr. Seidman\u2019s scientific expertise and Ms. Warden\u2019s strategic perspective and operational expertise will be important assets as Merck continues its journey to become the premier research-intensive biopharmaceutical company<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744027","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Christine (\u201cKricket\u201d) E. Seidman, professor, Harvard Medical School, and Kathy J. Warden, chairman, chief executive officer and president, Northrop Grumman Corporation, will join the company\u2019s Board of Directors effective March 16, 2020. Dr. Seidman and Ms. Warden will stand for election with the company\u2019s other directors in connection with Merck\u2019s Annual Meeting of Shareholders on May 26, 2020. With the addition of Dr. Seidman and Ms. Warden, the Merck board will include 14 members. \u201cWe are pleased to welcome Dr. Seidman and Ms. Warden to our board,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cBoth are highly respected leaders in their fields. Dr. Seidman\u2019s scientific expertise and Ms. Warden\u2019s strategic perspective and operational expertise will be important assets as Merck continues its journey to become the premier research-intensive biopharmaceutical company\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:37:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/\",\"name\":\"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2020-01-31T16:05:00+00:00\",\"dateModified\":\"2025-03-08T04:37:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Christine (\u201cKricket\u201d) E. Seidman, professor, Harvard Medical School, and Kathy J. Warden, chairman, chief executive officer and president, Northrop Grumman Corporation, will join the company\u2019s Board of Directors effective March 16, 2020. Dr. Seidman and Ms. Warden will stand for election with the company\u2019s other directors in connection with Merck\u2019s Annual Meeting of Shareholders on May 26, 2020. With the addition of Dr. Seidman and Ms. Warden, the Merck board will include 14 members. \u201cWe are pleased to welcome Dr. Seidman and Ms. Warden to our board,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cBoth are highly respected leaders in their fields. Dr. Seidman\u2019s scientific expertise and Ms. Warden\u2019s strategic perspective and operational expertise will be important assets as Merck continues its journey to become the premier research-intensive biopharmaceutical company","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:37:40+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/","name":"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2020-01-31T16:05:00+00:00","dateModified":"2025-03-08T04:37:40+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4bb5b5d6-a00d-4f04-8b0b-d4a635641a3a","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2020\/01\/1\/merck_logo.jpg","size":"21167","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Dr-Christine-Seidman-and-Kathy-Warden-Elected-to-Merck-Board-of-Directors-2020.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744027\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744027"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}